Clinical Trials Browser

Phase 1/2 × tislelizumab × Genitourinary × Clear all

NCT05661955 2025-11-21

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Phase 1/2 Active not recruiting

113 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma

NCT04666688 2025-02-12

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

44 enrolled

GastrointestinalGenitourinaryHead & Neck

Bile Duct Neoplasms, Carcinoma, Transitional Cell, Colonic Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04813107 2022-02-22

ANTICIPATE

Phase 1/2 Unknown

79 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT04922047 2021-06-11

TACBIN-01

Phase 1/2 Unknown

6 enrolled

Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urogenital Neoplasms, Urologic Neoplasms